ArticleGastroenterology research and practice2013
Update on the diagnosis and management of refractory coeliac disease.
Article in Gastroenterology research and practice, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease.Nature immunology · 2024Trial
- Nutritional remission without mucosal healing in type II refractory celiac disease: a case report.Frontiers in nutrition · 2026Article
- Seronegative refractory celiac disease complicated by severe malnutrition, duodenal ulceration, and thromboembolic events in a young male: a case report.Annals of medicine and surgery (2012) · 2025Article
- Novel Therapeutic Strategies for Celiac Disease.Middle East journal of digestive diseases · 2020Review
- Article
- Splenic volume differentiates complicated and non-complicated celiac disease.United European gastroenterology journal · 2017Article
- Article
- Intraepithelial lymphocytes, scores, mimickers and challenges in diagnosing gluten-sensitive enteropathy (celiac disease).World journal of gastroenterology · 2017Review
- Mechanisms and management of refractory coeliac disease.Nature reviews. Gastroenterology & hepatology · 2015Review
- Increased Mercury Levels in Patients with Celiac Disease following a Gluten-Free Regimen.Gastroenterology research and practice · 2015Article
- Th17, intestinal microbiota and the abnormal immune response in the pathogenesis of celiac disease.Gastroenterology and hepatology from bed to bench · 2015Review
- Hematopoietic stem cell transplantation for non-malignant gastrointestinal diseases.World journal of gastroenterology · 2014Review
- Optimal strategies to identify aberrant intra-epithelial lymphocytes in refractory coeliac disease.Journal of clinical immunology · 2014Article
- Severe refractory coeliac disease with response only to parenteral nutrition.Case reports in gastroenterology · 2014Article
- Refractory Celiac Disease Type II: A Case Report that Demonstrates the Diagnostic and Therapeutic Challenges.GE Portuguese journal of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A small subset of coeliac disease (CD) patients experiences persisting or recurring symptoms despite strict adherence to a gluten-free diet (GFD). When other causes of villous atrophy have been excluded, these patients are referred to as refractory celiac disease (RCD) patients. RCD can be divided in two types based on the absence (type I) or presence (type II) of an, usually clonal, intraepithelial lymphocyte population with aberrant phenotype. RCDI usually runs a benign course and may be difficult to be differentiated from uncomplicated, slow responding CD. In contrast, RCDII can be defined as low-grade intraepithelial lymphoma and frequently transforms into an aggressive enteropathy associated T-cell lymphoma with dismal prognosis. This paper describes the clinical characteristics of RCDI and RCDII, diagnostic approach, and the latest insights in treatment options.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.